Phathom Pharmaceuticals Profit Margin

The latest profit margin for PHAT is 72.79% as of September 2026. That compares with -102.09% in the prior-year period — up 171.3% year over year. That is above the Healthcare sector average of 19.13%. Investors often review this figure alongside Phathom Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PHAT's profit margin moved from -102.09% to 72.79% — a 171.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Phathom Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, PHAT currently prints 72.79% for profit margin, while the sector average sits near 19.13%. That is roughly 280.5% above the sector mean. Large gaps often invite a closer look at Phathom Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Phathom Pharmaceuticals converts resources into returns. At 72.79%, PHAT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -102.09% in the prior-year period — up 171.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PHAT's profit margin (72.79%), review year-over-year change from -102.09%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.